| First Author | Wang W | Year | 2022 |
| Journal | Cell Rep | Volume | 41 |
| Issue | 5 | Pages | 111582 |
| PubMed ID | 36323258 | Mgi Jnum | J:333431 |
| Mgi Id | MGI:7386622 | Doi | 10.1016/j.celrep.2022.111582 |
| Citation | Wang W, et al. (2022) Mobilizing phospholipids on tumor plasma membrane implicates phosphatidylserine externalization blockade for cancer immunotherapy. Cell Rep 41(5):111582 |
| abstractText | In "healthy" tumor cells, phosphatidylserine (PS) is predominately localized in the inner plasma membrane leaflet. During apoptosis, PS relocates to the outer leaflet. Herein, we established PS(out) tumor models with tumor cells lacking PS flippase component CDC50A, constantly exposing PS but alive. PS(out) tumors developed bigger than wild-type (WT) tumors, featuring M2 polarized tumor-associated macrophages (TAMs) and fewer tumor-antigen-specific T cells. The PS receptor TIM-3 is responsible for PS recognition. Employing an opposite tumor model, PS(in), with tumor cells lacking the PS scramblase Xkr8 and unable to expose PS during otherwise normal apoptosis, we find that the accumulated apoptotic tumor cells produce and release cyclic GAMP (cGAMP) to immune cells to activate the STING pathway, leading to TAM M1 polarization, suppressed interleukin (IL)-10 secretion, and natural killer (NK) cell cytotoxicity. Silencing Xkr8 in vivo by either short hairpin RNA (shRNA) or small interfering RNA (siRNA) to achieve a PS externalization blockade provides robust therapeutic anti-tumor efficiency. |
